Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant-resistant phenotype in breast cancer cells.
Matossian MD, Elliott S, Rhodes LV, Martin EC, Hoang VT, Burks HE, Zuercher WJ, Drewry DH, Collins-Burow BM, Burow ME. Matossian MD, et al. Among authors: burks he. Oncol Lett. 2021 May;21(5):380. doi: 10.3892/ol.2021.12641. Epub 2021 Mar 16. Oncol Lett. 2021. PMID: 33777204 Free PMC article.
Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes.
Matossian MD, Elliott S, Hoang VT, Burks HE, Phamduy TB, Chrisey DB, Zuercher WJ, Drewry DH, Wells C, Collins-Burow B, Burow ME. Matossian MD, et al. Among authors: burks he. PLoS One. 2017 Aug 3;12(8):e0177802. doi: 10.1371/journal.pone.0177802. eCollection 2017. PLoS One. 2017. PMID: 28771473 Free PMC article.
A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways.
Matossian MD, Burks HE, Elliott S, Hoang VT, Zuercher WJ, Wells C, Drewry DH, Kapadia N, Chang T, Yan T, Windsor GO, Nguyen K, Fang F, Nephew KP, Buechlein A, Rusch DB, Sabol RA, Ucar DA, Zabaleta J, Miele L, Bunnell BA, Collins-Burow BM, Burow ME. Matossian MD, et al. Among authors: burks he. Anticancer Drugs. 2020 Sep;31(8):759-775. doi: 10.1097/CAD.0000000000000962. Anticancer Drugs. 2020. PMID: 32796402 Free PMC article.
ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer.
Hoang VT, Matossian MD, Ucar DA, Elliott S, La J, Wright MK, Burks HE, Perles A, Hossain F, King CT, Browning VE, Bursavich J, Fang F, Del Valle L, Bhatt AB, Cavanaugh JE, Flaherty PT, Anbalagan M, Rowan BG, Bratton MR, Nephew KP, Miele L, Collins-Burow BM, Martin EC, Burow ME. Hoang VT, et al. Among authors: burks he. Front Oncol. 2020 Aug 3;10:1164. doi: 10.3389/fonc.2020.01164. eCollection 2020. Front Oncol. 2020. PMID: 32850332 Free PMC article.
NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells.
Matossian MD, Elliott S, Van Hoang T, Burks HE, Wright MK, Alzoubi MS, Yan T, Chang T, Wathieu H, Windsor GO, Hartono AB, Lee S, Zuercher WJ, Drewry DH, Wells C, Kapadia N, Buechlein A, Fang F, Nephew KP, Collins-Burow BM, Burow ME. Matossian MD, et al. Among authors: burks he. Breast Cancer Res Treat. 2021 Aug;189(1):49-61. doi: 10.1007/s10549-021-06295-4. Epub 2021 Jul 1. Breast Cancer Res Treat. 2021. PMID: 34196902
In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.
Matossian MD, Chang T, Wright MK, Burks HE, Elliott S, Sabol RA, Wathieu H, Windsor GO, Alzoubi MS, King CT, Bursavich JB, Ham AM, Savoie JJ, Nguyen K, Baddoo M, Flemington E, Sirenko O, Cromwell EF, Hebert KL, Lau F, Izadpanah R, Brown H, Sinha S, Zabaleta J, Riker AI, Moroz K, Miele L, Zea AH, Ochoa A, Bunnell BA, Collins-Burow BM, Martin EC, Burow ME. Matossian MD, et al. Among authors: burks he. Clin Transl Oncol. 2022 Jan;24(1):127-144. doi: 10.1007/s12094-021-02677-8. Epub 2021 Aug 9. Clin Transl Oncol. 2022. PMID: 34370182 Free PMC article.
Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V, Elliott S, Gilliam D, Pounder FN, Anbalagan M, Chrisey DB, Rowan BG, Burow ME, Collins-Burow BM. Rhodes LV, et al. Among authors: burks he. Breast Cancer Res Treat. 2014 Jun;145(3):593-604. doi: 10.1007/s10549-014-2979-6. Epub 2014 May 9. Breast Cancer Res Treat. 2014. PMID: 24810497 Free PMC article.
42 results